{
  "asset": {
    "name": "Palopegteriparatide (YORVIPATH\u00ae; TransCon\u00ae PTH)",
    "company": "Ascendis Pharma A/S",
    "ticker": "ASND",
    "target": "PTH receptor",
    "mechanism": "Prodrug of PTH (1-34) that provides active PTH within physiological range for 24 hours per day through transient conjugation technology",
    "modality": "Prodrug using TransCon technology",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Approved",
    "indications_in_development": [
      "Hypoparathyroidism in adults"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    4
  ],
  "_last_extracted": "2026-02-04T13:32:19.645957"
}